The suppression of EAU with α-MSH or MCR-agonists results in the establishment of ocular immune privilege and immune tolerance to ocular autoantigens, providing a potentially long-term resistance to the recurrence of uveitis.7,12 While the application of the RCI-gel suppresses EAU, whether this is associated with the reestablishment of ocular immune privilege and an immunosuppressive microenvironment will have to be studied. The gene discussed is STAMBP; the disease is uveitis.